Abstract Book - 26th ESPU Congress, Joint Meeting with ICCS + SPU + AAP/SOU + AAPU + SFU

ICCS S5-10

(P)

TRANSDERMAL OXYBUTYNIN NEOXY® TAPE 73.5 MG SURPASSES ORAL

OXYBUTYNIN HYDROCHLORIDE FOR CHILDREN WITH NEUROGENIC DETRUSOR

OVERACTIVITY.

Kazuyoshi JOHNIN

, Kenichi KOBAYASHI

, Akihiro KAWAUCHI

and Yasuyuki NAITOH

1) SHIGA UNIVERSITY OF MEDICAL SCIENCE, UROLOGY, Otsu, JAPAN - 2) KYOTO PREFECTURAL UNIVERSITY OF

MEDICINE, UROLOGY, Kyoto, JAPAN

PURPOSE

It is important to pursue the ideal conservative treatment for neurogenic bladder dysfunction. Transdermal oxybutynin

NEOXY

Tape 73.5 mg (NEOXY), which is applied daily and equivalent to oral oxybutynin hydrochloride (OXY) 6 mg,

became available in Japan from 2013. NEOXY has the advantage of providing an effective blood concentration of OXY

without constipation and dry mouth. We evaluated the efficacy and safety of NEOXY with or without overnight urinary

drainage (OUD) in children with neurogenic detrusor overactivity.

MATERIAL AND METHODS

Anticholinergic drugs were changed to NEOXY in 14 children with neurogenic detrusor overactivity who required more

than OXY 6 mg and additional intravesical OXY: median age 8.43 ± 3.55 (range, 4–15) years; 6 boys and 8 girls with

spina bifida (n = 11), cerebral palsy (n = 2), and unknown (n = 1). OUD was instituted in 6 patients, while 1 patient

received a vesicostomy. Five patients had reflux and renal scars. The reasons for changing anticholinergic drugs were:

severe constipation (n = 14), intractable urinary tract infection (UTI) (n = 6), incontinence (n = 5), taking medication

haphazardly (3), and dilation of the upper urinary tract (n = 2). A video urodynamic study (VUDS) was performed

before and after changing anticholinergic drugs.

RESULTS

After a 10.3 ± 3.3 month follow-up, UTI, incontinence, and hydronephrosis were improved. No patient experienced a

deterioration of constipation. Three patients ceased NEOXY therapy due to severe eruption within 1 month. At 3–8

months later, a VUDS showed that bladder capacity was unchanged (180 ± 33.2 to 200.8 ± 37.3 mL, p = 0.28) and

bladder compliance was significantly improved (5.01 ± 0.84 to 6.14 ± 0.59 mL/cmH

O, p < 0.05).

CONCLUSIONS

Transdermal oxybutynin NEOXY

Tape 73.5 mg is effective for the control of high intravesical pressure with minimal

drawbacks for children with neurogenic detrusor overactivity.